Amgen annual gross profit
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amgen Gross Profit Growth & History (AMGN)
Amgen's gross profit was $24.71B for fiscal 2025.
View full Amgen company overviewAmgen annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.71B | $4.15B | +20.17% |
| 2024 | 2024-12-31 | $20.57B | $827.0M | +4.19% |
| 2023 | 2023-12-31 | $19.74B | −$178.0M | −0.89% |
| 2022 | 2022-12-31 | $19.92B | $392.0M | +2.01% |
| 2021 | 2021-12-31 | $19.52B | $260.0M | +1.35% |
| 2020 | 2020-12-31 | $19.27B | $259.0M | +1.36% |
| 2019 | 2019-12-31 | $19.01B | −$640.0M | −3.26% |
| 2018 | 2018-12-31 | $19.65B | $866.0M | +4.61% |
| 2017 | 2017-12-31 | $18.78B | −$49.0M | −0.26% |
| 2016 | 2016-12-31 | $18.83B | $1.39B | +8.00% |
| 2015 | 2015-12-31 | $17.43B | $1.79B | +11.47% |
| 2014 | 2014-12-31 | $15.64B | $311.0M | +2.03% |
| 2013 | 2013-12-31 | $15.33B | $1.26B | +8.99% |
| 2012 | 2012-12-31 | $14.07B | $1.19B | +9.26% |
| 2011 | 2011-12-31 | $12.87B | — | — |
Amgen quarterly gross profit
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.24B | $1.07B | +17.43% |
| Q1 2026 | 2026-03-31 | $5.87B | $693.0M | +13.38% |
| Q4 2025 | 2025-12-31 | $6.89B | $916.0M | +15.33% |
| Q3 2025 | 2025-09-30 | $6.47B | $1.28B | +24.69% |
| Q2 2025 | 2025-06-30 | $6.17B | $1.02B | +19.72% |
| Q1 2025 | 2025-03-31 | $5.18B | $934.0M | +21.99% |
| Q4 2024 | 2024-12-31 | $5.97B | $890.0M | +17.51% |
| Q3 2024 | 2024-09-30 | $5.19B | $96.0M | +1.88% |
| Q2 2024 | 2024-06-30 | $5.15B | −$21.0M | −0.41% |
| Q1 2024 | 2024-03-31 | $4.25B | −$138.0M | −3.15% |
| Q4 2023 | 2023-12-31 | $5.08B | −$8.0M | −0.16% |
| Q3 2023 | 2023-09-30 | $5.10B | $33.0M | +0.65% |
| Q2 2023 | 2023-06-30 | $5.17B | $89.0M | +1.75% |
| Q1 2023 | 2023-03-31 | $4.38B | −$292.0M | −6.24% |
| Q4 2022 | 2022-12-31 | $5.09B | −$36.0M | −0.70% |
| Q3 2022 | 2022-09-30 | $5.06B | −$33.0M | −0.65% |
| Q2 2022 | 2022-06-30 | $5.08B | $195.0M | +3.99% |
| Q1 2022 | 2022-03-31 | $4.68B | $266.0M | +6.03% |
| Q4 2021 | 2021-12-31 | $5.13B | $391.0M | +8.25% |
| Q3 2021 | 2021-09-30 | $5.10B | $554.0M | +12.19% |
| Q2 2021 | 2021-06-30 | $4.89B | $469.0M | +10.61% |
| Q1 2021 | 2021-03-31 | $4.41B | $30.0M | +0.68% |
| Q4 2020 | 2020-12-31 | $4.74B | $109.0M | +2.36% |
| Q3 2020 | 2020-09-30 | $4.54B | $116.0M | +2.62% |
| Q2 2020 | 2020-06-30 | $4.42B | −$142.0M | −3.11% |
| Q1 2020 | 2020-03-31 | $4.38B | $150.0M | +3.55% |
| Q4 2019 | 2019-12-31 | $4.63B | −$277.0M | −5.65% |
| Q3 2019 | 2019-09-30 | $4.43B | −$46.0M | −1.03% |
| Q2 2019 | 2019-06-30 | $4.56B | −$93.0M | −2.00% |
| Q1 2019 | 2019-03-31 | $4.23B | −$168.0M | −3.82% |
| Q4 2018 | 2018-12-31 | $4.91B | $395.0M | +8.76% |
| Q3 2018 | 2018-09-30 | $4.47B | $10.0M | +0.22% |
| Q2 2018 | 2018-06-30 | $4.66B | $105.0M | +2.31% |
| Q1 2018 | 2018-03-31 | $4.40B | $196.0M | +4.66% |
| Q4 2017 | 2017-12-31 | $4.51B | −$86.0M | −1.87% |
| Q3 2017 | 2017-09-30 | $4.46B | −$26.0M | −0.58% |
| Q2 2017 | 2017-06-30 | $4.55B | $126.0M | +2.85% |
| Q1 2017 | 2017-03-31 | $4.20B | −$18.0M | −0.43% |
| Q4 2016 | 2016-12-31 | $4.60B | $338.0M | +7.94% |
| Q3 2016 | 2016-09-30 | $4.49B | $7.0M | +0.16% |
| Q2 2016 | 2016-06-30 | $4.42B | $288.0M | +6.96% |
| Q1 2016 | 2016-03-31 | $4.22B | $380.0M | +9.89% |
| Q4 2015 | 2015-12-31 | $4.26B | $110.0M | +2.65% |
| Q3 2015 | 2015-09-30 | $4.48B | $519.0M | +13.10% |
| Q2 2015 | 2015-06-30 | $4.14B | $37.0M | +0.90% |
| Q1 2015 | 2015-03-31 | $3.84B | $410.0M | +11.95% |
| Q4 2014 | 2014-12-31 | $4.15B | $378.0M | +10.03% |
| Q3 2014 | 2014-09-30 | $3.96B | $104.0M | +2.69% |
| Q2 2014 | 2014-06-30 | $4.10B | $289.0M | +7.59% |
| Q1 2014 | 2014-03-31 | $3.43B | $24.0M | +0.70% |
| Q4 2013 | 2013-12-31 | $3.77B | $355.0M | +10.40% |
| Q3 2013 | 2013-09-30 | $3.86B | $433.0M | +12.64% |
| Q2 2013 | 2013-06-30 | $3.81B | $362.0M | +10.50% |
| Q1 2013 | 2013-03-31 | $3.41B | $256.0M | +8.12% |
| Q4 2012 | 2012-12-31 | $3.42B | $164.0M | +5.04% |
| Q3 2012 | 2012-09-30 | $3.43B | $154.0M | +4.71% |
| Q2 2012 | 2012-06-30 | $3.45B | $157.0M | +4.77% |
| Q1 2012 | 2012-03-31 | $3.15B | $97.0M | +3.18% |
| Q4 2011 | 2011-12-31 | $3.25B | $63.0M | +1.98% |
| Q3 2011 | 2011-09-30 | $3.27B | $100.0M | +3.15% |
| Q2 2011 | 2011-06-30 | $3.29B | $231.0M | +7.55% |
| Q1 2011 | 2011-03-31 | $3.05B | $34.0M | +1.13% |
| Q4 2010 | 2010-12-31 | $3.19B | −$17.0M | −0.53% |
| Q3 2010 | 2010-09-30 | $3.17B | −$19.0M | −0.60% |
| Q2 2010 | 2010-06-30 | $3.06B | −$43.0M | −1.39% |
| Q1 2010 | 2010-03-31 | $3.02B | $259.0M | +9.38% |
| Q4 2009 | 2009-12-31 | $3.21B | — | — |
| Q3 2009 | 2009-09-30 | $3.19B | — | — |
| Q2 2009 | 2009-06-30 | $3.10B | — | — |
| Q1 2009 | 2009-03-31 | $2.76B | — | — |
Amgen gross profit trends
Over the last five fiscal years, Amgen's gross profit increased from $19.27B to $24.71B, a change of $5.45B. The latest reported quarter, Q2 2026, shows $7.24B.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗Community posts
Amgen–AstraZeneca combination cuts lung-cancer mortality risk by 58%
Amgen ($AMGN) disclosed detailed Phase 3 results showing that adding Imdelltra to AstraZeneca ($AZN)’s Imfinzi reduced the risk of death by 58% in first-line maintenance treatment of extensive-stage small-cell lung cancer. Median overall su ...
